Cases & Deals

Celgene licenses patents to Teva for marketing generic version of Focalin capsules and tablets

Client(s) Celgene Corporation

Jones Day represented Celgene in its licensing to Teva Pharmaceuticals of patents related to the manufacture of Celgene's Focalin XR capsules and Focalin IR tablets. The licensing was part of a settlement that concluded Hatch-Waxman patent litigation initiated by Celgene and Novartis Pharmaceuticals in response to Teva's filing of an abbreviated new drug application with the US FDA to market a generic equivalent of such drugs.